SY10-4 Clinical biomarkers to predict the efficacy of immune checkpoint inhibitors

Abstract

The survival benefit of immunotherapy using the PD-1/PD-L1 inhibitors and/or anti-CTLA-4 antibody has been demonstrated across multiple cancer types. Furthermore, the combination of chemotherapy and immunotherapy has been emerged in our clinical practice. Immunotherapy has become an essential part of the current cancer therapy. The biomarkers to predict the efficacy of immunotherapy may help to identify the patients who can get the greatest therapeutic effects. PD-L1 expression and tumor mutation burden are the most promising predictive biomarkers in identifying who have achieved a response after being treatment with immunotherapy. However, the predictive value of these biomarkers remains insufficient. Recently, the variety of investigation for predictive biomarkers has been reported, such as neutrophil to lymphocyte ratio, microbiome, and occurrence of immune-related adverse events. I want to review these clinical biomarkers in JSMO 2021 meeting.